Statement from Planned Parenthood Federation of America Senior Director of Medical Services Dr. Deborah Nucatola on New
HPV Vaccine Study in the Journal Pediatrics
Not exact matches
Inovio's
vaccine against
HPV is currently in Phase II clinical
studies, and Kim says «about 50 percent» of the subjects in that trial are defeating the disease.
In essence, the
HPV vaccine will continue to be advised against during pregnancy until more research confirms what this
study has found.
A 2016 Pediatrics
study found that, within six years of the first
vaccine's introduction in 2006, infections with the four
HPV types covered decreased 64 percent among 14 - to 19 - year - old girls.
Published in The Journal of Rural Health, the
study involved research nurses administering the first dose of the
HPV vaccine series free of charge to Appalachian Kentucky women aged 18 - 26.
Harpal Kumar, Cancer Research UK's chief executive, said: «As someone with an ethnic minority background myself and as a parent, this
study highlights a very worrying reason why girls from some minority groups don't get the
HPV vaccine.
Study authors intend to perform additional research in the future to follow up on their estimate of how well the current
vaccines protect against
HPV - associated cancers.
«Based on epidemiological
studies, the 9vHPV
vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of
HPV - related vulvar and vaginal cancer, 70 to 85 percent of high - grade cervical disease in females, and approximately 90 percent of
HPV - related anal cancer and genital warts in males and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Moffitt.
The researchers, including those from Moffitt Cancer Center, published the final results of a
study showing the newest
vaccine is highly effective at preventing
HPV infection and disease.
«Delivery of the
HPV vaccine in safety - net settings is critically important because uninsured African - American and Hispanic women have higher rates of cervical cancer,» said Dr. Jasmin Tiro, Associate Professor of Clinical Sciences at UT Southwestern, who led the
study.
Physician assistant
studies majors Jamie Phillipich, left, and Margie Webb surveyed 1,000 first - year students to assess the influence media has on the perception of
HPV and
vaccine compliance.
«
HPV vaccines could dramatically reduce the incidence of
HPV - associated cancers, but uptake of these
vaccines is far lower than for other routine childhood and teen immunizations,» said Kevin A. Henry, PhD, an assistant professor in the Department of Geography and Urban
Studies at Temple University in Philadelphia and member of Fox Chase Cancer Center's Cancer Prevention and Control program.
Group C was composed of women with counts below 200, the defining level of AIDS for which response to an
HPV vaccine had not yet been
studied.
Co-administration of the 9 - valent
HPV vaccine with diphtheria, tetanus, pertussis, polio, and meningococcal
vaccines could also be completed at the same visit, which has been demonstrated in clinical
studies.
The
study was sponsored and funded by Merck & Co, which manufactures the quadrivalent and nonavalent
HPV vaccines.
«Although data clearly indicate better immune responses and
vaccine efficacy against both genital warts and cervical dysplasia when vaccination occurs before age 14, this
study suggests that
HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut,» explained co-author Rebecca Perkins, MD, MSc, assistant professor of Obstetrics and Gynecology at Boston University School of Medicine and a gynecologist at Boston Medical Center.
A recent
study in the journal Human
Vaccines & Immunotherapeutics, showed that two doses of the
HPV - 16 / 18 AS04 - adjuvanted
vaccine Cervarix (GlaxoSmithKline) are non-inferior to three - doses in the current schedule.
They have become a valuable resource for biologists, enabling momentous scientific breakthroughs including the development of the polio
vaccine the Nobel Prize winning
studies defining the role of telomerase in aging, and research on the causative role of human papillomavirus (
HPV) in some types of cervical cancer.
A new
study finds that a simple reminder via electronic health record systems may go a long way in encouraging patients to get the
HPV vaccine that protects against cervical cancer.
While an
HPV vaccine became available over 10 years ago, a
study led by the Yale School of Public Health finds that there is «substantial» room for improvement in the way it is recommended and discussed.
Thus, as Americans have expanded their sexual repertoire, as an October
study from The Journal of Sexual Medicine highlighted, prevalence of
HPV can sweep quickly through a population — especially one that is unprotected by a
vaccine or consistent condom use.
Giuliano and scientists in 18 countries
studied more than 14,000 women between the ages of 16 and 26, comparing the effects of Gardasil to other
HPV vaccines.
A retracted
study linking the
vaccine for human papillomavirus (
HPV) to behavioral problems in mice has been republished by a different journal.
The
study relates to a particular type of
vaccine (killed) against a particular virus, influenza, though the findings might hold true for other killed
vaccines and for those
vaccines consisting only of proteins produced by GM in bacteria, yeast or insect cells, against diseases such as hepatitis B (HBV) and human papilloma virus (
HPV, the causative agent of cervical cancer).
THURSDAY, Sept. 29, 2016 (HealthDay News)-- The
vaccine against human papillomavirus (
HPV) infection, which doctors believe causes most cases of cervical cancer, appears even more effective than believed, a new
study finds.
According to a
study published this week in The Lancet, an
HPV vaccine can indeed protect women ages 24 to 45 from getting the sexually transmitted virus.
The Efficacy
studies for both the
HPV and «flu»
vaccines appear to over state results due to the same improper methods.
A multi-stage experimental
study of a large and diverse sample of American adults (N = 1,500) found evidence that cultural cognition generates disagreement about the risks and benefits of the
HPV vaccine.
«As the leading reproductive health care provider and advocate, Planned Parenthood is encouraged by the Kaiser Permanente
study showing that the
HPV vaccine does not increase sexual activity in girls.
Studies show that the
HPV vaccine doesn't lead to people having more sex or sex at a younger age.